Researchers found that PD-1/PD-L1 antibody monotherapy did not reduce the risk of BMs in patients with NSCLC (HR = 1.87; 95%CI = 1.13–3.11) [45]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.